Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol 2018 Feb;93(2):E49-E52
Date
11/23/2017Pubmed ID
29164656Pubmed Central ID
PMC5760282DOI
10.1002/ajh.24980Scopus ID
2-s2.0-85037372411 (requires institutional sign-in at Scopus site) 13 CitationsAuthor List
Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, Litzow MR, Stone RM, Erba HPAuthor
Laura Michaelis MD Chief, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AgedAged, 80 and over
Antimetabolites, Antineoplastic
Female
Frail Elderly
Humans
Leukemia, Myeloid, Acute
Male
